Teva Pharmaceutical Industries has completed its acquisition of Emalex Biosciences, paying $700 million upfront with up to $200 million in additional milestone payments.

 

The move is designed to strengthen its late-stage neuroscience pipeline and accelerate its “Pivot to Growth” strategy.

 

The deal centers on ecopipam, an investigational treatment for pediatric Tourette syndrome that has already reached Phase 3 and received both FDA Orphan Drug and Fast Track designations. Teva says a US NDA submission is expected in the second half of 2026, following recently published Phase 3 results in JAMA Neurology.

 

“This acquisition reflects our Pivot to Growth strategy in action, advancing our innovative pipeline through focused, capital-efficient business development,” said Richard Francis, President and Chief Executive Officer of Teva. 

 

“It adds a late-stage opportunity with potential to address a significant unmet need in Tourette syndrome, and with our deep neuroscience expertise, we are well-positioned to advance this program.”

 

Ecopipam is a first-in-class selective dopamine D1 receptor antagonist designed to reduce dopamine signaling linked to repetitive and compulsive behaviors. 

 

In Phase 3 testing, it met its primary endpoint of time to relapse in pediatric patients, showing statistical significance versus placebo. The therapy was generally well tolerated, with reported adverse events including somnolence, insomnia, anxiety, fatigue, and headache.

 

Tourette syndrome remains a chronic neurodevelopmental disorder that begins in childhood, often between ages 5 and 10, marked by involuntary motor and vocal tics that can significantly disrupt daily life. Existing treatments help some patients, but many continue to experience inadequate symptom control or limiting side effects—leaving a clear unmet need.

 

Emalex Biosciences, originally formed by Paragon Biosciences, advanced ecopipam through clinical development and prepared the NDA submission package prior to the acquisition.

 

With the deal now closed, Teva is betting that ecopipam can become a key near-term driver in its evolving neuroscience portfolio—and a potential breakthrough for patients with limited treatment options.